SHANNON KOVELESKIE: Open Payments
NPI 1225417942 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,925 in 108 payments from 20 companies in 2025. Trend: 2023 $1,717 · 2024 $1,424 · 2025 $2,925
Food & beverage: $2,732Education: $193
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 14 | $669 |
| GlaxoSmithKline, LLC. | 24 | $604 |
| AstraZeneca Pharmaceuticals LP | 14 | $462 |
| Novartis Pharmaceuticals Corporation | 12 | $181 |
| Genentech USA, Inc. | 8 | $149 |
| Verona Pharma, Inc. | 6 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| GENZYME CORPORATION | 6 | $123 |
| Grifols USA, LLC | 4 | $100 |
| Organon LLC | 4 | $80 |
Products named: DUPIXENT, NUCALA, FASENRA, Xolair, AIRSUPRA, Ohtuvayre, ZORYVE, TEZSPIRE.
Industry payments across LA — which companies pay providers there.
